Selective Targeting of Nurr1 for Alzheimer’s Disease
Official title: Selective Targeting of Nurr1 in Alzheimer's Disease
Funded at Saint Louis University · NIH-11618618 · Data updated 2026-11-12
A small study tests new brain-targeted compounds to help people with Alzheimer’s by reducing inflammation and protecting brain cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 10, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $541,009 |
| NIH project number | 1R56AG100922-01 |
| Project ID | NIH-11618618 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with Alzheimer’s disease or related neurodegenerative conditions, likely in early to mid-stages, who could participate in future translational steps if the program advances.
✕Less likely to help
Patients without Alzheimer’s or related conditions or those not aligned with future trial pathways may not benefit.
What this research studies
If you or a loved one has Alzheimer’s disease or a related dementia, this project explores a molecule called Nurr1 that may calm brain inflammation and support neuron health. The study builds on early work that identified promising Nurr1 compounds and aims to improve their specificity, potency, and ability to reach the brain. Researchers will examine how these compounds interact with brain cells in models relevant to Alzheimer’s and gather data that could guide future human trials. The goal is to develop a more effective treatment approach that could slow disease progression and improve quality of life for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies that slow Alzheimer’s progression and help patients maintain memory and daily functioning longer.
How similar studies have gone: Previous work has identified Nurr1 as a promising target, but this project focuses on more potent and brain-penetrant compounds; translational success remains to be demonstrated.
Where this research is happening
-
Saint Louis University
Saint Louis, United States Active
Researchers
- Principal investigator: De Vera, Ian Mitchelle Sayo — Saint Louis University
- Study coordinator: De Vera, Ian Mitchelle Sayo
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.